{
    "nctId": "NCT04249440",
    "briefTitle": "Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer",
    "officialTitle": "Preoperative Systemic Therapy Versus Upfront Surgery in HER2 Positive Early Breast Cancer: a Prospective Nested Case-control Study in Real World",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, HER2, Preoperative Systemic Treatment",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1067,
    "primaryOutcomeMeasure": "Disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. HER2 positive\n2. early invasive breast cancer (cT1-3N0-1M0)\n3. using one-year trastuzumab as anti-HER2 treatment\n\nExclusion Criteria:\n\n1. Exclude metastasis and recurrent breast cancer\n2. using trastuzumab less than a year",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}